Fig. 3: Pathway and network analysis of severity-discriminatory mRNAs and metabolites in infants with bronchiolitis.

A The top 25 biological pathways according to the false discovery rate (FDR) value of each pathway in the functional enrichment joint-pathway analysis with Kyoto encyclopedia of genes and genomes (KEGG) terms using the severity-discriminatory 401 mRNAs and 38 metabolites. The horizontal axis represents the negative log10-transformed FDR. Plot color represents the percentage of hit components (mRNAs and metabolites) in each pathway. Plot size represents the impact of each pathway (i.e., pathway impact). This impact is computed by first determining the centrality of each component within a given pathway and then dividing the sum of these centrality measures by the total centrality measures for all components within the corresponding pathway. B The visualization of a pathway-based network generated from the severity-discriminatory 401 mRNAs and 38 metabolites. The dark green squares and red hexagons correspond to the severity-discriminatory mRNAs and metabolites identified in the analysis. The light green squares and pink hexagons represent the mRNAs and metabolites, derived from the KEGG and Edinburgh human metabolic network (EHMN) databases, that are adjacent to (i.e., surrounding) the severity-discriminatory mRNAs and metabolites. The size of the squares and hexagons represents the magnitude of the betweenness centrality of each node. The color of each edge represents the type of pathway related to the connected nodes, while the thickness of each edge indicates the magnitude of the edge betweenness of each edge. HIF-1 hypoxia-inducible factor 1, IL-17 interleukin 17, KEGG Kyoto encyclopedia of genes and genomes, NF-kappa B nuclear factor kappa B, NOD nucleotide-binding oligomerization domain, PI3K-Akt phosphatidylinositol 3-kinase / protein kinase B, RNA ribonucleic acid, TNF tumor necrosis factor.